Targeting a specific receptor in aggressive brain tumors with radiation therapy
Official title: IL13Ra2-targeted radioimmunotherapy for glioblastoma
Funded at University of Tx Md Anderson Can Ctr · NIH-11139747 · Data updated 2026-11-12
This study is testing a new treatment that uses targeted radiation to attack glioblastoma cells, aiming to help patients by reducing damage to healthy tissue and improving their chances of recovery.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 5, 2025 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $432,134 |
| NIH project number | 1R21CA294042-01A1 |
| Project ID | NIH-11139747 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who express the IL13Rα2 receptor.
✕Less likely to help
Patients with glioblastoma who do not express the IL13Rα2 receptor or those with other types of brain tumors may not benefit from this research.
What this research studies
This research focuses on using radioimmunotherapy to target the IL13Rα2 receptor, which is commonly found on glioblastoma cells. By delivering radiation specifically to these cancer cells, the treatment aims to minimize damage to surrounding healthy tissues. The approach utilizes beta-emitting isotopes that can effectively kill tumor cells, even those that are resistant to traditional therapies. Patients with glioblastoma may benefit from this targeted treatment, which seeks to improve outcomes and reduce recurrence rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with radioimmunotherapy targeting specific receptors in various cancers, indicating potential for success in this novel application.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Krebs, Simone — University of Tx Md Anderson Can Ctr
- Study coordinator: Krebs, Simone
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.